Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
5-FU medac 50 mg/ml, Injektionslösung, Tecentriq 1 200 mg concentrate for solution for infusion, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, Oxaliplatin medac 5 mg/ml concentrate for solution for infusion
Institut für biomedizinische Analytik NMR-Imaging GmbH
locally advanced resectable adenocarcinoma of the oesophagogastric junction or the stomach
1 trial -
ACIDE FOLIQUE CCD 5 mg, comprimé, PLACEBO D'ASPIRINE PROTECT, ASPIRINE PROTECT 100 mg, comprimé gastro-résistant, PLACEBO D'ACIDE FOLIQUE
Pari Pharma GmbH
Patients presenting to ENT emergencies with a unilateral sudden sensorineural hearing loss (SSNHL). SSNHL is defined according to the American ENT society guidelines criteria as a subset of SSNHL that is sensorineural in nature, occurs within a 72 hour window, and consists of a decrease in hearing of ≥30 decibels affecting at least 3 consecutive frequencies: 1. A history of an idiopathic and unilateral sudden decrease in hearing > 72 hours and <15 days. 2. A unilateral sensorineural hearing loss demonstrable on a pure‐tone audiogram at the time of entry into the trial. 3. No other neurological signs except the eight cranial nerve defect; no other types of hearing loss as conductive forms of hearing impairment. 4. No history of fluctuating sensorineural hearing loss or otologic disease.
1 trial -
Abraxane 5 mg/ml powder for dispersion for infusion., Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, Fluorouracil Accord 50 mg/ml šķīdums injekcijām vai infūzijām, CALCIUM FOLINATE , GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Oxaliplatin Accord 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Ipsen Pharma
Metastatic Pancreatic Adenocarcinoma
1 trial -
Anifrolumab, Anifrolumab Placebo
AstraZeneca AB
Polymyositis or dermatomyositis according to 2017 EULAR / ACR classification criteria
1 trial -
Attentin 10 mg Tablette, Dexamfetamine sulfate 20 mg modified-release capsule, Placebo for Test 1 - 5 mg, Attentin 5 mg, Tablette, Placebo for test 2 - 10 mg, Placebo for test 1 - 10 mg, Placebo for test 2 - 20 mg, Dexamfetamine sulfate 15 mg modified-release capsule, Placebo for test 2 - 15 mg, Dexamfetamine sulfate 10 mg modified-release capsule
Medice Arzneimittel Pütter GmbH & Co. KG
Patients with ADHD (according to ICD-10 / DSM-5)
1 trial -
Capecitabine Accord 150 mg film-coated tablets, Fluorouracil 25 mg/ml Solution for Injection or Infusion, Irinotecan Accord 20 mg/ml Solution à diluer pour perfusion, OXALIPLATINE ARROW LAB 5 mg/mL, solution à diluer pour perfusion, Leucovorin-Teva 10 mg/ml Concentrate for Solution for Infusion
Cancer Prevention Pharma (Ireland) Limited
Stage III colorectal cancer
1 trial -
Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Capecitabine Accord 500 mg film-coated tablets, Inflectra 100 mg powder for concentrate for solution for infusion, IMFINZI 50 mg/mL concentrate for solution for infusion., The Placebo is formulated as 26 mM histidine/histidine-HCl, 275 mM trehalose dihydrate, 0.02% (w/v) polysorbate 80, pH 6.0., Fluorouracil Injection, 50 mg/ml, solution for injection, Mycophenolate Mofetil Accord 250 mg capsules, Capecitabine Accord 150 mg film-coated tablets
AstraZeneca AB
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma
1 trial -
DEXAMETHASONE, Dexamethasonfosfaat Accord 4 mg/ml oplossing voor injectie/infusie, Kyprolis 10 mg powder for solution for infusion, Paracetamol 1000mg Tablets, Imnovid 2 mg hard capsules, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, LYNOZYFIC 200 mg concentrate for solution for infusion, Dermodrin 30 mg/2 ml soluție injectabilă, Imnovid 3 mg hard capsules, DEXAMETHASONE, Co-Trimoxazole 80/400mg Tablets, Kyprolis 30 mg powder for solution for infusion, LYNOZYFIC 5 mg concentrate for s
Pharma Mar S.A.
Relapsed Refractory Multiple Myeloma
1 trial -
Dexamethasone Tablets BP 2.0mg, Fortecortin® 2 mg Tabletten, Lenalidomide Accord 15 mg hard capsules, CARVYKTI 3.2 × 10^6 – 1.0 × 10^8 cells dispersion for infusion, Lenalidomide Mylan 5 mg hard capsules, Lenalidomide Mylan 20 mg hard capsules, VELCADE 3.5 mg powder for solution for injection, Lenalidomide Mylan 20 mg hard capsules, Lenalidomide Accord 10 mg hard capsules, Lenalidomide Accord 2.5 mg hard capsules, FLUDARABINE , Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 10 mg hard capsules
Janssen-Cilag International N.V.
Multiple Myeloma
1 trial -
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category
Aquestive Therapeutics
Epilepsy
1 trial -
Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion
Gilead Sciences International Limited
Non-small cell lung cancer
1 trial -
FLUDARABINE PHOSPHATE, DAUNORUBICIN HYDROCHLORIDE, BUSULFAN, Azacitidine Accord 25 mg/mL powder for suspension for injection, CYTARABINE, THIOTEPA
Fondazione Telethon ETS
Higher-risk-myelodysplastic syndromes
1 trial -
Fortecortin® 2 mg Tabletten, teclistamab, Lenalidomide Mylan 25 mg hard capsules, JNJ-64407564, Dexamethasone Tablets BP 2.0mg, Lenalidomide Accord 10 mg hard capsules, JNJ-64407564, Lenalidomide Mylan 15 mg hard capsules, Lenalidomide Accord 5 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Lenalidomide Mylan 5 mg hard capsules, Privigen 100 mg/ml solution for infusion, DARZALEX 1800 mg solution for injection, Lenalidomide Accord 15 mg hard capsules, Lenalidomide Accord 25 mg hard capsules, Privigen 100 mg
Janssen-Cilag International N.V.
Multiple Myeloma
1 trial -
HOLOXAN 2000 mg, poudre pour usage parentéral, DETICENE 100 mg, poudre et solvant pour solution pour perfusion, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion
Institut für biomedizinische Analytik NMR-Imaging GmbH
Resectable, non-metastatic soft-tissue sarcoma (STS)
1 trial -
IMJUDO 20 mg/ml concentrate for solution for infusion., PACLITAXEL SANDOZ 6 mg/ml, solution à diluer pour perfusion, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, CARBOPLATINE KABI 10 mg/ml, solution à diluer pour perfusion, IMFINZI 50 mg/mL concentrate for solution for infusion, Tecentriq 840 mg concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatine Accord 1 mg/ml concentraat voor op
Institut für biomedizinische Analytik NMR-Imaging GmbH
Synchronous oligometastatic non-small cell lung cancer (NSCLC)
1 trial -
Irinotecan Accord, 20 mg/ml, koncentrat do sporządzania roztworu do infuzji, Bendadocel 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Irinotecan Bendalis 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Docetaxel Hikma 80 mg/4 ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Bendalis 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cyramza 10 mg/ml concentrate for solution for
AstraZeneca AB
Gastric cancer, Advanced/Metastatic Gastric cancer, Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
1 trial -
Irinotecan HCl-trihydraat Accord 20 mg/ml concentraat voor oplossing voor infusie, Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie, Folinezuur Sandoz 10 mg/ml, oplossing voor injectie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie
Disc Medicine
Non-metastatic resectable pancreatic cancer
1 trial -
Irinotecan HCl-trihydraat Fresenius Kabi 20 mg/ml, concentraat voor oplossing voor infusie, Folinezuur Sandoz 10 mg/ml, oplossing voor injectie, Gemcitabine Sandoz 40 mg/ml, concentraat voor oplossing voor infusie, Fluorouracil Accord 50 mg/ml, oplossing voor injectie of infusie, Oxaliplatine Fresenius Kabi 5 mg/ml concentraat voor oplossing voor infusie
Disc Medicine
non-metastatic (borderline) resectable pancreatic cancer
1 trial -
Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, 5-FU medac 50 mg/ml, Injektionslösung, Calciumfolinat Sandoz 10 mg/ml – Injektions-/Infusionslösung, SANIFOLIN polvere per soluzione iniettabile, Irinotecan Kabi 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Paclitaxel Aurobindo 6 mg/ml concentrato per soluzione per infusione, Paclitaxel Accord 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, Cyramza 10 mg/ml c
Institut für biomedizinische Analytik NMR-Imaging GmbH
advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctions, who failed prior line of palliative chemotherpay
1 trial -
JNJ-63723283, JNJ-63723283, Gemcitabina Accord 100 mg/ml concentrato per soluzione per infusione., JNJ-17000139, GEMCITABINE ACCORD 100 mg/ml, solution à diluer pour perfusion, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., Gemcitabine100 mg/ml Concentrate for Solution for Infusion, Gemcitabin Accord 100 mg/ml Konzentrat zur Herstellung einer Infusionslösung
Janssen-Cilag International N.V.
Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder
1 trial -
Kyprolis 60 mg powder for solution for infusion, Kyprolis 30 mg powder for solution for infusion, DARZALEX 1800 mg solution for injection, ENDOXAN omhulde tablet, omhulde tabletten, 50 mg, Cesnicabtagene autoleucel, Kyprolis 10 mg powder for solution for infusion, Dexamethason Teva 4 mg, tabletten, Bortezomib Accord 3.5 mg powder for solution for injection, Empliciti 300 mg powder for concentrate for solution for infusion., Dexamethason Activase 2 mg tabletten, Pomalidomide Accord 4 mg hard capsules, Emplic
Disc Medicine
relapsed/refractory multiple myeloma
1 trial -
LETROZOLE, PALBOCICLIB, Inavolisib placebo, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, Letrozol STADA® 2,5 mg Filmtabletten, INAVOLISIB, IBRANCE 100 mg film-coated tablets, INAVOLISIB, RIBOCICLIB, PALBOCICLIB, RIBOCICLIB, PALBOCICLIB
Roche Registration Limited
Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Hormone Receptor-Positive, human epidermal growth factor receptor 2- (HER2-) negative advanced breast cancer
1 trial -
Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Diphenhydramine Hydrochloride Tablets 50 mg
Roche Registration Limited
Progressive multiple sclerosis (PMS)
1 trial -
Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Paracetamol Accord 1000 mg comprimate efervescente, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg
Roche Registration Limited
Multiple sclerosis (MS)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources